Abstract

Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine

Author(s): Catry Emilie, Colsoul Marie-Louise, Closset Melanie, Hubert Justine, Soumoy Laura, Bihin Benoit, Thiry Emmanuell, Jamart Jacques, Hecq Jean-Daniel, Galanti Laurence

Issue: May/Jun 2022 - Volume 26, Number 3

Page(s): 248-254

Download in electronic PDF format for $75
  • Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine Page 1
  • Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine Page 2
  • Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine Page 3
  • Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine Page 4
  • Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine Page 5
  • Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine Page 6
  • Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine Page 7

Abstract

Death rattle, which could often be associated with a pulmonary fluid overload, occurs in 25% to 90% of dying patients. The co-administration of scopolamine (anticholinergic drug) and bumetanide (loop diuretic) could be considered in order to avoid unnecessary fluid overload at end-stage of life. The objective of this study was to investigate the physical and chemical stabilities of the admixture bumetanide and scopolamine in order to prepare them in advance by a centralized intravenous additive service in-hospital pharmacy. The stability of the lowest (LOW) concentration was evaluated on five polypropylene syringes containing the admixture bumetanide (Burinex, 2 mg/4 mL) and scopolamine (0.25 mg/mL) at 41.67 µg/mL and 5.21 µg/mL. The highest (HIGH) concentration with 125 µg/mL of bumetanide and 31.25 µg/mL of scopolamine was evaluated on five polypropylene syringes. All syringes were stored for 18 days at 5°C ± 3°C. Periodic samples were visually and microscopically examined to observe any particle appearance or color change. The pH and absorbance at 3 wavelengths (350 nm, 410 nm, and 550 nm) were monitored. The concentrations were measured by ultra-high performance liquid chromatography–photodiode array detection, using a newly developed method. During the 18 days of test, there was no change in color or appearance of opacity, turbidity, or precipitation, and the pH remained stable. Mean concentrations of bumetanide and scopolamine at LOW and HIGH concentrations after 18 days remained statistically unchanged. The lower limits of the 95% confidence intervals of both molecules at LOW and HIGH concentrations remained higher than a 90% threshold of concentration, indicating the mixture was chemically stable. Degradation rates of bumetanide and scopolamine content at LOW and HIGH concentrations should not exceed a maximum of 0.70% every 10 days. This study was the first to show that the admixture of bumetanide and scopolamine is physically and chemically stable at two concentrations used in a palliative-care unit. This combination available in ready-to-use polypropylene syringes presents numerous advantages for patient’s comfort and safety.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
May/Jun 2022
Pg. 248-254
Sep/Oct 2009
Pg. 438-439
Author(s): Gupta Vishnu D
May/Jun 2014
Pg. 233
Author(s): Allen Loyd V Jr
Jan/Feb 2014
Pg. 61
Author(s): Allen Loyd V Jr
Jul/Aug 2001
Pg. 310-312
Author(s): Allen Loyd V Jr
May/Jun 2020
Pg. 242-245
Author(s): Ngim Kenley, Patel Jalpa
Nov/Dec 2020
Pg. 473-478
Author(s): Allen Loyd V Jr
May/Jun 2020
Pg. 238-241
May/Jun 2013
Pg. 254-261
Jul/Aug 2013
Pg. 307-311
Author(s): McElhiney Linda F
Jan/Feb 2020
Pg. 30-36
Author(s): Dillon L R
Jan/Feb 2020
Pg. 44-50
Author(s): Allen Loyd V Jr
Sep/Oct 2017
Pg. 356
Author(s): Allen Loyd V Jr
May/Jun 2021
Pg. 222-229
Author(s): Allen Loyd V Jr
Nov/Dec 2022
Pg. 522-526
Jul/Aug 2016
Pg. 326
Author(s): Allen Loyd V Jr
Mar/Apr 2021
Pg. 131-139
Author(s): Allen Loyd V Jr
Jul/Aug 2017
Pg. 347-351
May/Jun 2014
Pg. 190-200
Sep/Oct 2007
Pg. 426-432